|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Receivable from Bendistillery, Inc. | |||||||||||||||||||
| Cash and Cash Equivalents | |||||||||||||||||||
| Prepaid Expenses | |||||||||||||||||||
| Accounts Receivable, net of allowance of $1,207,367 in 2026 and $1,269,590 in 2025 | |||||||||||||||||||
| Inventory, net of allowance of $6,596,096 in 2026 and $0 in 2025 | |||||||||||||||||||
| Income Tax Receivable | |||||||||||||||||||
| Current Portion of Settlement Asset and Receivables | |||||||||||||||||||
| Receivable Loans from Extrax NM - Current | |||||||||||||||||||
| Assets held for sale | |||||||||||||||||||
| Other Current Assets | |||||||||||||||||||
| Total Current Assets | |||||||||||||||||||
| Restricted Cash | |||||||||||||||||||
| Goodwill carrying value | |||||||||||||||||||
| Total investment | |||||||||||||||||||
| Investment in Bendistillery and Bend Spirits | |||||||||||||||||||
| Investment in Bendistillery | |||||||||||||||||||
| Net Deferred Tax Asset | |||||||||||||||||||
| Fixed Assets, less accumulated depreciation of $1,690,642 in 2026 and $1,608,543 in 2025 | |||||||||||||||||||
| Security and State Licensing Deposits and Bonds | |||||||||||||||||||
| Finance Lease Right-of-Use Asset, net of Right-of-Use Asset Amortization of $206,008 in 2022 | |||||||||||||||||||
| Operating Lease Right-of-Use Asset, net of Right-of-Use Asset Amortization of $591,243 in 2026 and $457,742 in 2025 | |||||||||||||||||||
| Debt Financing Costs | |||||||||||||||||||
| Non-Current Portion of Settlement Asset and Receivables | |||||||||||||||||||
| Receivable Unit Loans from Extrax NM - Non-Current | |||||||||||||||||||
| Total Assets | |||||||||||||||||||
| Current Liabilities | |||||||||||||||||||
| Finance Lease Liability | |||||||||||||||||||
| Operating Lease Liability | |||||||||||||||||||
| Deferred Revenue | |||||||||||||||||||
| Minimum Earnout Consideration to be paid pursuant to the Oculus Merger Agreement ($200,000 in cash, and $800,000 in the form of 160,000 shares of common stock valued at $5.00 per share) | |||||||||||||||||||
| Minimum Earnout Consideration pursuant to the Oculus Merger Agreement ($200,000 in cash, and $800,000 in the form of 160,000 shares of common stock valued at $5.00 per share) | |||||||||||||||||||
| Income Tax Payable | |||||||||||||||||||
| Collab Commissions and Royalties Payable | |||||||||||||||||||
| Accounts Payable and Accrued Expenses | |||||||||||||||||||
| Accounts Payable - Related Party | |||||||||||||||||||
| Note Payable - Related Party | |||||||||||||||||||
| Preferred Stock Dividends Payable | |||||||||||||||||||
| Notes Payable to Surety Bank | |||||||||||||||||||
| Interest Payable to Surety Bank | |||||||||||||||||||
| Total Current Liabilities | |||||||||||||||||||
| Non-Current Liabilities | |||||||||||||||||||
| Operating Lease Liability | |||||||||||||||||||
| Note Payable to Surety Bank | |||||||||||||||||||
| Net Deferred Tax Liability | |||||||||||||||||||
| Total Non-Current Liabilities | |||||||||||||||||||
| Total Liabilities | |||||||||||||||||||
| Commitments and Contingencies | |||||||||||||||||||
| Common Stock, $0.001 par value; 100,000,000 shares authorized, and:14,822,678 shares issued and outstanding at June 30, 2026 14,822,678 shares issued and outstanding at December 31, 2025 | |||||||||||||||||||
| Additional Paid-in Capital | |||||||||||||||||||
| 142,000 shares of Deferred Contingent Stock issuable upon instruction by the respective Deferred Contingent Stock Recipients at September 30, 2023; no shares of Deferred Contingent Stock issuable at December 31, 2022 | |||||||||||||||||||
| 142,000 shares of Deferred Contingent Stock issuable upon instruction by the respective Deferred Contingent Stock Recipients at December 31, 2023; no shares of Deferred Contingent Stock issuable at December 31, 2022 | |||||||||||||||||||
| 142,000 shares of Deferred Contingent Stock issuable upon instruction by the respective Deferred Contingent Stock Recipients at June 30, 2026 and December 31, 2025 | |||||||||||||||||||
| Accumulated Deficit | |||||||||||||||||||
| Total Shareholders' Equity | |||||||||||||||||||
| Total Liabilities and Shareholders' Equity | |||||||||||||||||||
| Preferred stock value | |||||||||||||||||||
| Series A Convertible Preferred Stock | |||||||||||||||||||
| Series B Convertible Preferred Stock | |||||||||||||||||||
Loading...